43 results about "Pneumococcal infections" patented technology

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and / or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and / or a cytolysoid polypeptide, or an active variant or fragment thereof.

The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and / or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.

There is provided a method of diagnosing a disease state in a subject. The disease state is caused or effected by pneumococcal infection. The method includes obtaining a biological test sample from the subject. The biological sample includes at least one metabolite selected from the group consisting of citrate, trigonelline, acetylcarnitine, acetone, myo-inositol, 3-hydroxybutyrate, glucose and carnitine. A respective concentration of each one of the at least one metabolite is compared with a predetermined concentration value associated with a corresponding one of the at least one metabolite. The predetermined concentration value is indicative of the disease state. For example, the biological sample includes any one of citrate, trigonelline, acetylcamitine, acetone, myoinositol, 3-hydroxybutyrate, glucose and carnitine. As a further example, the biological samples include any combination of citrate, trigonelline, acetylcamitine, acetone, myo-inositol, 3-hydroxybutyrate, glucose and carnitine. As a further example, the biological sample includes each one of citrate, trigonelline, acetylcamitine, acetone, myoinositol, 3-hydroxybutyrate, glucose and carnitine.

There are provided inter alia compounds of formula (I) wherein R1, R2, R3, R4a and R4b are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.

Provided herein are compositions designed to reduce or prevent pneuomococcal infections, nasal carriage, nasal colonization, and central nervous system invasion. Provided herein is a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof that can elicit an anti-neuraminidase immune response. Further provided are methods of making and using the compositions disclosed herein. Specifically provided are methods of generating antibodies in a subject comprising administering to the subject an agent or composition taught herein. Also provided are methods of reducing or preventing nasal carriage or pneumococcal infection in a subject comprising administering to the subject a composition taught herein.

The invention relates to the field of pharmaceutical chemistry, and particularly relates to a novel compound for treating pneumococcal infectious diseases, and use of the compound. According to the compound disclosed by the invention, the structural general formula is as shown in the formula I. The compound disclosed by the invention, especially ZCL039 can be applied to preparing a leucyl-tRNA synthetase inhibitor, and medicines for treating pneumococcal infectious diseases, and can be used for inhibiting or killing pathogenic microorganisms such as pneumococcus and the like. The compound disclosed by the invention has the advantage of activity of resisting pneumococcus, has a strong function of inhibiting SpLeuRS, is low in toxicity on human cells, and provides a new path for treatment of the pneumococcal infectious diseases.

The present invention relates to compositions and methods for the treatment of infection caused by Streptococcus pneumonia. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.

The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and / or active immunisation against a microorganism that can be killed by opsonophagocytic cells. <??>The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. <??>The invention also discloses the use of antibodies against said proteins for passive immunisation.